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Introduction {#sec001}
============

PCa is the most frequent cancer in men\[[@pone.0218645.ref001]\], with increasing prevalence.\[[@pone.0218645.ref002]\] Screening of PSA can detect PCa at an earlier stage. However, elevation of PSA levels in serum requires prostate biopsy to confirm if it is caused by PCa. Unfortunately, a biopsy can be painful and may cause complications such as infection and bleeding.\[[@pone.0218645.ref003]\] Fewer than 50% of patients with elevated PSA levels have positive biopsies (41.49%\[[@pone.0218645.ref004]\] and 30.7%\[[@pone.0218645.ref005]\]). The low detection rate is partly explained by the blind approach of transrectal ultrasound scan (TRUS)-prostate biopsy,\[[@pone.0218645.ref006]\] which leads to a high rate of unnecessary biopsies.

PSA is secreted by normal and malignant prostate tissues. It follows therefore that PSA is an organ-specific rather than a cancer-specific serum marker, which means that the elevation of PSA levels in patients with negative biopsies can be caused by benign prostatic hyperplasia (BPH) and prostatitis.\[[@pone.0218645.ref002]\] Compensating for the limitations of PSA tests is achieved by adjusting PSA levels according to prostate volume (PV), known as PSA density (PSAD).\[[@pone.0218645.ref007], [@pone.0218645.ref008]\]

According to MRI imaging of prostate zonal anatomy, the prostate comprises a peripheral zone (PZ), a transition zone (TZ), a central zone, and an anterior fibromuscular stroma.\[[@pone.0218645.ref009]\] The PZ is the source of 75% to 85% of PCa.\[[@pone.0218645.ref010]\] Compared with PSA levels alone, the accuracy of diagnosing PCa will be improved using PZ- adjusted PSA levels (PSA density of peripheral zone \[PSADPZ\]), derived from the ratio of PSA and peripheral zone volume, or TZ-adjusted PSA levels (PSA density of transition zone \[PSADTZ\]), derived from the ratio of PSA and transition zone volume (TZV).\[[@pone.0218645.ref011]--[@pone.0218645.ref014]\]

Since TRUS was introduced by Watanabe in 1967, its use to measure prostate volume has been important because of its improving image quality.\[[@pone.0218645.ref015]\] However, measurement of PV using TRUS is less accurate compared with MRI.\[[@pone.0218645.ref014], [@pone.0218645.ref016], [@pone.0218645.ref017]\] Further, MRI assesses PV with high reproducibility and accuracy compared with TRUS because of interobserver variability associated with the latter.\[[@pone.0218645.ref018]\]

Here we used logistic regression analysis and modeling to determine the efficacy of PSA levels, which were adjusted using MRI-based prostate zonal volume, and optimized models to differentiate PCa from BPH before initial prostate biopsy and for predicting HR-PCa among Chinese patients.

Materials and methods {#sec002}
=====================

Study population {#sec003}
----------------

This was a retrospective cohort study conducted in the Laboratory of Urology and the Department of Urology of Fujian Medical University Union Hospital (Fuzhou, China) from January 2012 to March 2018. Data were collected from 422 consecutive patients who underwent mp-MRI before initial TRUS-guided 13-core prostate biopsy. Patients met any of the criteria before initial prostate biopsy as follows: elevated PSA levels (≥10 ng·ml^-1^), suspected cancer on digital rectal examination (DRE), hyperechoic or hypoechoic TRUS, or abnormal MRI findings. For PSA between 4 ng·ml^-1^ to 10 ng·ml^-1^, the biopsy criterion was free PSA\<16% or PSAD \>0.15 ng·ml^-2^. We excluded patients with a history of prostate surgery or pathological examination revealing tumors other than adenocarcinoma. Ethical approval was acquired from the Institutional Review Board of Fujian Medical University Union Hospital. The approval form of consent was obtained by written with approval number of 2018KY078, and patients provided written informed consent before the study commenced. All data were fully anonymized before been accessed.

Clinical date and variable definitions {#sec004}
--------------------------------------

Data on clinical characteristics including age, body mass index (BMI), PSA, percentage free PSA (free to total PSA), MR findings, PV, PSAD, TZV, PSADTZ, PZV, PSADPZ, alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) were collected before biopsy. PV was calculated for each patient using the prolate ellipsoid formula (volume = 0.52 × length × width × height) using prostate T2WI MR images (axial and sagittal). MR imaging was performed using a 3.0T MR scanner (Siemens Medical Solutions, Erlangen, Germany). The interpretation of MRI findings was performed by a radiologist and a urologist to measure prostatic width and height on axial fat-saturated T2WI MR images and prostatic length on sagittal images ([Fig 1](#pone.0218645.g001){ref-type="fig"}). PZV = PV--TZV. and PSAD, PSADTZ and PSADPZ were calculated as ratios of PSA to total PV, TZV and PZV(PZV = PV---TZV), respectively.

![Prostate location and MR imagine plane.\
**(Yellow: Transition zone; Blue: Peripheral zone.).** (a, b, c.) Axial fat-saturated T2WI MR images of prostate. (d, e, f.) Sagittal fat-saturated T2WI MR images of prostate. (b, e.) Blue line (1, 2, 3.) depicting the width, height and length of transition zone. (c, f.) Red line (1, 2, 3.) depicting the width, height and length of prostate.](pone.0218645.g001){#pone.0218645.g001}

Patients underwent standard TRUS-guided 13-core prostate biopsies. Four and two cores were acquired from the left PZ and left TZ, respectively, and four and two cores were acquired from the right PZ and right TZ, respectively. The last core was acquired depending on the imaging abnormalities. All biopsy specimens were reviewed by a pathologist to diagnose prostate cancer. According to the 2018 EAU clinical guidelines for prostate cancer, HR-PCa is defined as PSA ≥20 ng·ml^-1^, with or without T stage ≥T2b, and with or without Gleason score ≥7. We selected these parameters to distinguish patients with or without HR-PCa.

Statistical analysis {#sec005}
--------------------

The values of continuous variables (Age, BMI, PSA, percentage free PSA, PV, PSAD, TZV, PSADTZ, PZV, PSADPZ, ALP and LDH) were not normally distributed. Therefore, Wilcoxon signed rank tests were used to evaluate these parameters, which are reported as the median with interquartile ranges. Categorical variables (MR findings) were calculated using the chi-squared test, shown as counts with percentages. Stepwise multivariate logistic regression analyses were performed to identify independent parameters associated with PCa and HR-PCa. We evaluated the diagnostic accuracy of base model 1 that integrated the clinical predictors PSA, MR, PV and PSAD. The logistic prediction models with TZV (base model 1 + TZV), with PSADTZ (base model 1 + PSADTZ), with PZV (base model 1 + PZV) and with PSADPZ (base model 1 + PSADPZ) were used to evaluate the biopsy results (with or without PCa). We evaluated the diagnostic accuracy of base model 2 that incorporated the clinical predictors MR, PV and PSAD as well as the logistic prediction models with TZV (base model 2 + TZV) and with PSADTZ (base model 2 + PSADTZ) to evaluate biopsy results (HR-PCa or no HR-PCa). The predictive accuracy of these variables and prediction models were calculated using the AUC. The cut-off value, sensitivity, specificity and positive and negative likelihood ratios were computed. Statistical significance was defined as P-value \<0.05. Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS version 20.0, Chicago, IL, USA).

Results {#sec006}
=======

Patients' baseline characteristics were summarized in [Table 1](#pone.0218645.t001){ref-type="table"}. Of the 422 patients who underwent prostate biopsies, those of 185 (43.84%) were positive. Compared with patients with negative biopsies, the ages of patients with positive biopsies were significantly advanced and their values of PSA, PSAD, PSADTZ, PZV, PSADPZ, LDH and percentage of abnormal MR were higher as well. And lower PV and TZV values were found in patients with positive biopsies (each P \<0.05). Among 185 patients, 71.35% (n = 132) were diagnosed with HR-PCa ([Table 2](#pone.0218645.t002){ref-type="table"}). The ages of patients with HR-PCa were significantly advanced and their PV, PSAD, PSADTZ, PZV and PSADPZ values were higher as well. Their LDH and TZV values were lower compared with those of patients without HR-PCa (each P \<0.05).

10.1371/journal.pone.0218645.t001

###### Clinical characteristics of patients with no PCa and PCa at the initial biopsy.

![](pone.0218645.t001){#pone.0218645.t001g}

  Parameters                                                 Overall               no PCa                PCa                   OR (95% CI)            P value
  ---------------------------------------------------------- --------------------- --------------------- --------------------- ---------------------- ---------
  Patients,n(%)                                              422                   237(56.16)            185(43.84)                                   
  Age[^a^](#t001fn002){ref-type="table-fn"},years            69(63--75)            69(62.5--74)          71(64--76)            1.031(1.007--1.056)    0.012
  BMI[^a^](#t001fn002){ref-type="table-fn"},kg·m^-2^         23.40(21.50--25.50)   23.30(21.73--24.98)   23.50(20.80--25.80)   1.001(0.943--1.062)    0.560
  PSA[^a^](#t001fn002){ref-type="table-fn"}, ng·ml^-1^       13.56(8.62--31.18)    11.50(7.55--18.54)    26.10(11.34--97.90)   1.039(1.029--1.050)    \<0.001
  percent free PSA[^a^](#t001fn002){ref-type="table-fn"},%   12.60(8.90--18.93)    13.20(9.80--18.25)    11.80(8.00--20.25)    9.368(1.601--54.804)   0.364
  MR,n(%)                                                                                                                      5.616(3.409--9.253)    \<0.001
      Normal                                                 132 (31.28)           108 (45.57)           24 (12.97)                                   
      Abnormal                                               290 (68.72)           129 (54.43)           161 (87.03)                                  
  PV[^a^](#t001fn002){ref-type="table-fn"}, ml               52.41(38.99--71.97)   59.37(41.97--82.65)   45.05(34.02--59.83)   0.978(0.970--0.986)    \<0.001
  PSAD[^a^](#t001fn002){ref-type="table-fn"}, ng·ml^-2^      0.27(0.15--0.64)      0.19(0.12--0.29)      0.63(0.25--1.56)      7.870(4.500--13.766)   \<0.001
  TZV[^a^](#t001fn002){ref-type="table-fn"}, ml              19.94(10.84--36.88)   32.14(17.43--48.50)   12.35(7.56--19.30)    0.926(0.910--0.943)    \<0.001
  PSADTZ[^a^](#t001fn002){ref-type="table-fn"}, ng·ml^-2^    0.60(0.32--2.04)      0.36(0.25--0.60)      2.48(0.77--6.10)      2.411(1.902--3.055)    \<0.001
  PZV[^a^](#t001fn002){ref-type="table-fn"}, ml              28.96(23.02--38.25)   27.79(21.59--35.81)   32.90(23.94--42.24)   1.027(1.012--1.043)    \<0.001
  PSADPZ[^a^](#t001fn002){ref-type="table-fn"}, ng·ml^-2^    0.53(0.28--1.02)      0.42(0.25--0.63)      0.86(0.39--2.21)      2.157(1.660--2.803)    \<0.001
  ALP[^a^](#t001fn002){ref-type="table-fn"},U·L^-1^          71(59--86)            73(59--86)            70(58--86.25)         1.003(1.000--1.006)    0.907
  LDH[^a^](#t001fn002){ref-type="table-fn"},U·L^-1^          179(155--206)         176(151--203)         181(158--210)         1.006(1.002--1.011)    0.028

PCa prostate cancer, OR odds ratio, PV prostate volume, PSAD PSA density, TZV transitional zone volume, PSADTZ PSA density of the transitional zone, PZV peripheral zone volume, PSADPZ PSA density of the peripheral zone.

^a^ Continuous variables are shown as the median value and interquartile range

10.1371/journal.pone.0218645.t002

###### Clinical characteristics of patients with no HR-PCa and HR-PCa at the initial biopsy.

![](pone.0218645.t002){#pone.0218645.t002g}

  Parameters                                                Overall                no HR-PCa              HR-PCa                  OR (95% CI)           P value
  --------------------------------------------------------- ---------------------- ---------------------- ----------------------- --------------------- ---------
  Patients, n(%)                                            185                    53 (28.65)             132 (71.35)                                   
  Age [^a^](#t002fn002){ref-type="table-fn"}, years         71(64--76)             68(62.5--73.5)         72(65--77)              1.051(1.010--1.094)   0.012
  BMI [^a^](#t002fn002){ref-type="table-fn"},kg·m^-2^       23.5(20.8--25.8)       24.4 (21.9--26.0)      23.4 (20.7--25.7)       0.932(0.848--1.023)   0.139
  MR,n(%)                                                                                                                         3.250(1.372--7.698)   0.007
      Normal                                                25 (13.51)             13 (24.53)             12 (9.09)                                     
      Abnormal                                              160 (86.49)            40 (75.47)             120 (90.91)                                   
  PV [^a^](#t002fn002){ref-type="table-fn"}, ml             43.67 (32.51--59.07)   40.62(25.22--56.46)    46.28 (34.69--59.98)    1.023(1.007--1.040)   0.009
  PSAD [^a^](#t002fn002){ref-type="table-fn"}, ng·ml^-2^    0.76(0.29--1.74)       0.30(0.19--0.46)       1.09(0.45--1.90)        2.214(1.406--3.487)   \<0.001
  TZV [^a^](#t002fn002){ref-type="table-fn"}, ml            12.95 (7.60--20.48)    16.42(9.38--25.42)     11.62 (7.03--18.33)     0.980(0.956--1.003)   0.020
  PSADTZ[^a^](#t002fn002){ref-type="table-fn"}, ng·ml^-2^   3.05(0.98--7.06)       1.05(0.48--2.41)       3.83 (1.69--8.58)       1.081(1.008--1.160)   \<0.001
  PZV [^a^](#t002fn002){ref-type="table-fn"}, ml            32.90(23.94--42.24)    28.25 (21.82--38.36)   35.11 (25.33--43.81)    1.033(1.006--1.061)   0.015
  PSADPZ[^a^](#t002fn002){ref-type="table-fn"}, ng·ml^-2^   1.06(0.46--2.21)       0.45(0.27--0.69)       1.59(0.65--2.45)        4.691(2.529--8.533)   \<0.001
  ALP [^a^](#t002fn002){ref-type="table-fn"}, U·L^-1^       70(58--86.25)          64(55--75)             76(61--94)              1.026(1.008--1.044)   0.001
  LDH [^a^](#t002fn002){ref-type="table-fn"}, U·L^-1^       181(158--210)          174(156--202)          185.5 (158.25--214.5)   1.009(1.000--1.018)   0.095

HR-PCa high-risk prostate cancer, OR odds ratio, PV prostate volume, PSAD PSA density, TZV transitional zone volume, PSADTZ PSA density of the transitional zone, PZV peripheral zone volume, PSADPZ PSA density of the peripheral zone.

^a^ Continuous variables are shown as the median value and interquartile range

Multivariate logistic regression analysis revealed that PSA, MR, PV, PSAD, TZV, PSADTZ, PZV and PSADPZ served as independent predictors of PCa ([Table 3](#pone.0218645.t003){ref-type="table"}). Further, multivariate logistic regression analysis incorporating backward elimination selection was used to select independent predictors of HR-PCa in model building. Stepwise multivariate analysis that excluded Age, PZV, PSADPZ and LDH revealed that MR, PV, PSAD, TZV and PSADTZ were independent predictors of HR-PCa ([Table 4](#pone.0218645.t004){ref-type="table"}).

10.1371/journal.pone.0218645.t003

###### Multivariate logistic regression analysis of predictors associated with PCa at the initial biopsy.

![](pone.0218645.t003){#pone.0218645.t003g}

  Parameters   Multivariate analysis adjusted OR for PCa   Multivariate analysis adjusted 95% CI for PCa   P value
  ------------ ------------------------------------------- ----------------------------------------------- ---------
  Age          1.025                                       0.989--1.061                                    0.171
  PSA          1.044                                       1.018--1.072                                    0.001
  MR           2.856                                       1.455--5.608                                    0.002
  PV           1.077                                       1.044--1.112                                    \<0.001
  PSAD         0.018                                       0.001--0.330                                    0.007
  TZV          0.841                                       0.795--0.890                                    \<0.001
  PSADTZ       2.494                                       1.158--5.370                                    0.020
  PZV          1.189                                       1.124--1.258                                    \<0.001
  PSADPZ       2.016                                       1.147--3.544                                    0.015
  LDH          1.001                                       0.994--1.009                                    0.688

PCa prostate cancer, OR odds ratio, PV prostate volume, PSAD PSA density, TZV transitional zone volume, PSADTZ PSA density of the transitional zone, PZV peripheral zone volume, PSADPZ PSA density of the peripheral zone.

10.1371/journal.pone.0218645.t004

###### Multivariate logistic regression analysis of predictors associated with HR-PCa at the initial biopsy (backward elimination selection procedure).

![](pone.0218645.t004){#pone.0218645.t004g}

  Parameters   Multivariate analysis adjusted OR for HR-PCa   Multivariate analysis adjusted 95% CI for HR-PCa   P value
  ------------ ---------------------------------------------- -------------------------------------------------- ---------
  MR           3.576                                          1.095--11.683                                      0.035
  PV           1.154                                          1.094--1.217                                       \<0.001
  PSAD         106.450                                        12.424--912.037                                    \<0.001
  TZV          0.810                                          0.742--0.883                                       \<0.001
  PSADTZ       0.708                                          0.549--0.915                                       0.008

HR-PCa high-risk prostate cancer, OR odds ratio, PV prostate volume, PSAD PSA density, TZV transitional zone volume, PSADTZ PSA density of the transitional zone.

Tables [5](#pone.0218645.t005){ref-type="table"} and [6](#pone.0218645.t006){ref-type="table"} show the ROC curve analysis of the different clinical parameters of PCa and HR-PCa. When we chose the best cut-off values of PSA, PSADTZ, PSADPZ (29.165, 0.705 and 0.975, respectively) for predicting PCa, the sensitivities were 48.9%, 78.3% and 48.4%, respectively and the specificities were 91.5%, 81.4% and 89.8%, respectively. The best cut-off values for predicting HR-PCa using PV, TZV, PSADTZ were 28.18, 19.23 and 1.658, respectively; sensitivities were 92.4%, 78.0% and 75.6%, respectively; and specificities were 35.8%, 56.6% and 28.3%, respectively.

10.1371/journal.pone.0218645.t005

###### The AUC and cut-off values for predicting biopsy outcome and their sensitivity, specificity, positive and negative likelihood ratios for PCa and no PCa.

![](pone.0218645.t005){#pone.0218645.t005g}

  ----------------------------------------------------------------------------------------------------------------------------------------
  Parameters             AUC (95% CI)          Cut-off value   Sensitivity\   Specificity\   Positive likelihood\   Negative likelihood\
                                                               (%)            (%)            ratio                  ratio
  ---------------------- --------------------- --------------- -------------- -------------- ---------------------- ----------------------
  PSA                    0.723(0.672--0.774)   29.165          48.9           91.5           0.8179                 0.6964

  MR                     0.661(0.610--0.713)   ---             ---            ---            ---                    ---

  PV                     0.339(0.287--0.391)   52.73           65.4           60.8           0.5657                 0.6924

  PSAD                   0.794(0.749--0.839)   0.365           65.8           83.9           0.7614                 0.7586

  TZV                    0.197(0.155--0.238)   19.415          76.2           27.8           0.4517                 0.5944

  PSADTZ                 0.862(0.826--0.899)   0.705           78.3           81.4           0.7667                 0.8277

  PZV                    0.607(0.552--0.661)   36.80           40.2           80.1           0.6119                 0.6318

  PSADPZ                 0.704(0.652--0.756)   0.975           48.4           89.8           0.7874                 0.6903

  Base model 1           0.842(0.803--0.881)   0.513           67.4           88.6           0.8219                 0.7769

  Base model 1+ TZV      0.906(0.879--0.934)   0.422           85.3           80.5           0.7735                 0.8752

  Base model 1+ PSADTZ   0.880(0.846--0.914)   0.354           80.4           83.5           0.7918                 0.8451

  Base model 1+ PZV      0.906(0.879--0.934)   0.422           85.3           80.5           0.7735                 0.8752

  Base model 1+ PSADPZ   0.851(0.813--0.888)   0.459           69.6           87.3           0.8105                 0.7863
  ----------------------------------------------------------------------------------------------------------------------------------------

PCa prostate cancer, AUC area under the receiver-operating characteristic curve, PV prostate volume, PSAD PSA density, TZV transitional zone volume, PSADTZ PSA density of the transitional zone, PZV peripheral zone volume, PSADPZ PSA density of the peripheral zone, Base model 1 PSA + PV + PSAD + MR.

10.1371/journal.pone.0218645.t006

###### The AUC and cut-off values for predicting biopsy outcome and their sensitivity, specificity, positive and negative likelihood ratios for HR-PCa and no HR-PCa.

![](pone.0218645.t006){#pone.0218645.t006g}

  Parameters              AUC (95% CI)          Cut-off value   Sensitivity(%)   Specificity(%)   Positive likelihood ratio   Negative likelihood ratio
  ----------------------- --------------------- --------------- ---------------- ---------------- --------------------------- ---------------------------
  MR                      0.577(0.482--0.672)   ---             ---              ---              ---                         ---
  PV                      0.625(0.531--0.720)   28.18           92.4             35.8             0.7819                      0.6542
  PSAD                    0.732(0.642--0.823)   0.56            72.5             18.9             0.6900                      0.2163
  TZV                     0.393(0.301--0.485)   19.23           78.0             56.6             0.8174                      0.5081
  PSADTZ                  0.729(0.639--0.818)   1.658           75.6             28.3             0.7242                      0.3177
  Base model 2            0.809(0.748--0.870)   0.8347          54.2             69.2             0.8142                      0.3777
  Base model 2 + TZV      0.893(0.849--0.937)   0.8130          70.2             98.1             0.9892                      0.5693
  Base model 2 + PSADTZ   0.814(0.755--0.874)   0.8197          58               1.9              0.5955                      0.0178

HR-PCa high-risk prostate cancer, AUC area under the receiver-operating characteristic curve, PV prostate volume, PSAD PSA density, TZV transitional zone volume, PSADTZ PSA density of the transitional zone, Base model 2 PV + PSAD + MR.

Base model 1 for PCa integrated PSA, PV, PSAD and MR. The AUC of base model 1 + TZV or base model 1 + PZV for PCa was higher compared with those of PSA alone, base model 1, base model 1 + PSADTZ, or base model 1 + PSADPZ. The AUC of base model 1 + TZV was 0.906 for PCa, which was similar to that of base model 1 + PZV. Base model 2 for HR-PCa integrated PV, PSAD and MR. The AUC of base model 2 + TZV was 0.893 for HR-PCa, which was higher compared with that of base model 2 or base model 2 + PSADTZ ([Fig 2](#pone.0218645.g002){ref-type="fig"}).

![**Receiver-operating characteristic curves depicting the accuracy of predictors of PCa (a.) and HR-PCa (b.) at the initial biopsy.** Base model 1, PSA + PV + PSAD + MR; Base model 2, PV + PSAD + MR. ^1^Base model 1 + TZV and Base model 1 + PZV had the same AUC.](pone.0218645.g002){#pone.0218645.g002}

Discussion {#sec007}
==========

Definitive diagnosis of prostate cancer depends on histopathological verification of adenocarcinoma in a prostate biopsy that may lead to complications such as infection, bleeding and anxiety.\[[@pone.0218645.ref003]\] Therefore, it is inappropriate to use a prostate biopsy to perform routine active surveillance on asymptomatic people with elevated serum levels of PSA.\[[@pone.0218645.ref002]\] Reducing the complications of biopsies requires careful selection of patients who are likely to benefit. Although a series of parameters and imaging methods are available to improve patient selection, there is no consensus on the optimal criteria. To address the situation, here we evaluated the reliability of PV and associated zone-adjusted PSA levels for detecting prostate cancer.

Measurements of PSA level in serum are considered to help detect prostate cancer.\[[@pone.0218645.ref002]\] However, the elevation of PSA levels may be caused by BPH rather than prostate cancer.\[[@pone.0218645.ref019]\] Consequently, numerous studies report the predictive value of PV-adjusted PSA for PCa. For example, a study of the utility of PSAD and PSA of 659 patients demonstrated that the AUC of PSAD (0.73) is higher than that of PSA (0.61) for diagnosing PCa.\[[@pone.0218645.ref007]\] A study of 172 patients found that the AUC of PSA significantly increases from 0.683 to 0.806 using PSAD.\[[@pone.0218645.ref012]\] However, a study of 109 patients with clinically localized prostate cancer found that PSAD fails to outperform PSA for preoperative prediction of prostate cancer.\[[@pone.0218645.ref020]\]

We were unable to determine the reasons for the dissimilarities among these studies. However, measurement of prostate volume may be less accurate using TRUS compared with mp-MRI or specimen after radical prostatectomy. To increase the accuracy of our findings, we used mp-MRI-based parameters and found a higher AUC of PSAD (0.794) than that of PSA (0.723). Multivariate regression analysis for predicting PCa indicated that PSAD was superior to PSA for making decisions on selecting patients to undergo biopsy.

Here we found patients with PCa had lower PV compared with those without PCa (45.05 vs 59.37 ml, P \<0.001). We assumed that BPH might contribute to the increase of PV to a greater extent than PCa. PCa usually arises from the PZ, and most BPH originates in the TZ.\[[@pone.0218645.ref010], [@pone.0218645.ref012]\] Our result are consistent with this opinion. Compared with patients without PCa, lower TZV (12.35 vs 32.14 ml, P \<0.001) and higher PZV (32.9 vs 27.79 ml, P \<0.001) was found in patients with PCa, which indicates the diagnostic potential of TZV and PZV for diagnosing PCa.

PSA mainly leaks from the TZ.\[[@pone.0218645.ref010], [@pone.0218645.ref012]\] Therefore, we hypothesized that prostate-zone adjusted PSA serves as a more effective parameter than PSAD and PSA for the diagnosis of PCa, which is consistent with published studies. For example, a study of 1712 patients who underwent TRUS-guided prostate biopsies found that the AUC of PSADTZ is 0.766 and those of PSAD and PSA are 0.749 and 0.585, respectively, for diagnosing PCa.\[[@pone.0218645.ref021]\] Another study of 189 patients stratified according to PSA levels ranging from 4.0--10.0 ng·ml^-1^ or 10.1--20.0 ng·ml^-1^ found that the AUC of PSADTZ were higher (0.702 and 0.730, respectively), compared with those of PSA (0.569 and 0.463, respectively) as well as the AUC associated with specificity and sensitivity.\[[@pone.0218645.ref022]\] Here, we found that the AUC of PSADTZ (0.862) was significantly higher compared with that of PSA (0.723) or that of the AUC of any other single parameter, followed by the AUC of PSAD (0.794). Further, we show here that our data provide a compelling argument that supports the conclusion that the utility of PSADTZ for performing surveillance for patients at risk of PCa is more effective compared with standard variables such as PSA.

Dissimilarities between single parameters are occasionally reported, and models that integrate multiple parameters were developed to predict prostate cancer more accurately. For example, a model developed based on 862 men who underwent TRUS found that the highest AUC (0.905) was associated with their best model that integrates age, PSA, percentage free PSA, PV, DRE and TURS, which was higher compared with that of PSA alone (0.672). \[[@pone.0218645.ref023]\] This study further evaluated the predictive accuracy of the best models (0.90 in the internal validation). Another study integrated PSAD and the percentage free PSA as their best model (AUC = 0.824) for the probability of detecting prostate cancer in all patients; and the AUC for PSA, percentages of free PSA and PSAD were 0.662, 0.676 and 0.786 respectively.\[[@pone.0218645.ref024]\] To validate the utility of their model, the best model was applied to an independent cohort of 88 patients. The results showed its AUC is 0.883, which is greater than those of PSA (0.704) and PSAD (0.854) for predicting PCa in the test cohort.

In the present study, we integrated PSA, PV, PSAD and MR as base model 1. When integrated with TZV or PZV, these variables equally served as the best model (AUC = 0.906 for predicting PCa). Interestingly, the AUC associated with PSADTZ was the highest among all single parameters, but when integrated into the base model 1, its AUC is 0.880, which is lower compared with that of the base model 1 + TZV or PZV. We assumed that integrated models eliminated confounding factors of single parameter. We concluded therefore that our best models are superior to those of the studies cited.

As described by the International Society of Urological Pathology 2014 grade, patients diagnosed with PCa are stratified using the combination of serum PSA level, Gleason score and clinical staging (cTNM).\[[@pone.0218645.ref002]\] Risk stratification can help clinicians select treatment strategies such as curative or deferred treatment and predict the outcomes of patients with different levels of risk. However, risk stratification relies on prostate biopsy which may cause the complications mentioned above. Therefore, we conclude that a novel method based on noninvasive parameters may be superior to prostate biopsy for risk stratification.

In the present study, compared with no HR-PCa, patients diagnosed with HR-PCa had higher PV (46.28 vs 40.62 ml, P \<0.001) and PZV (35.11 vs 28.25 ml, P \<0.001), possibly indicating the higher rate of tumor growth and pathological progression, which more likely may be stratified as HR-PCa, which corresponds with the origin of most PCa in the PZ. For example, one study found that 44% of 380 patients had extracapsular extensions, indicating that PSAD is an independent predictor that distinguishes HR-PCa from PCa and predicts PSA-free survival.\[[@pone.0218645.ref025]\] Further, the 5-year PSA-free survival rates are 82.9% for patients with PSAD \<0.468 ng·ml^-2^ and 50.7% for those with PSAD \>0.468 ng·ml ^-2^ (P \<0.001). Here we show that PSAD had the highest AUC (0.732) with a cut-off value of 0.56 ng·ml^-2^, followed by the AUC of PSADTZ (0.729), which distinguished HR-PCa from PCa. We assumed that the discrepancy in the PSAD cut-off values may be explained by different imaging techniques used to measure PV. We believe it is therefore reasonable to conclude that PSAD and PSADTZ may serve as optimal noninvasive parameters when applied to evaluate risk stratification among patients with PCa.

Other models are available to predict HR-PCa. For example, a study of 362 patients with PCa developed a predictive model (AUC = 0.894) by integrating age, PSA, PV, DRE and TRUS.\[[@pone.0218645.ref023]\] Another study of 216 patients PCa included 97 patients with HR-PCa. Age, PSA, percentage free PSA, PV, DRE and TRUS were integrated into one model with an AUC of 0.830 for predicting HR-PCa.\[[@pone.0218645.ref026]\] The discrepant combinations of models in many reports differ widely.

In the present study, we used PZV and zone-adjusted PSA based on mp-MRI rather than TRUS to build models which is different from those developed by other investigations. We found that TZV and PSADTZ were crucial contributors to our prediction model (AUC = 0.893 and 0.814, respectively), which were simultaneously integrated into our base model 2 (PV+PSAD+MR). We were unaware of a consensus opinion for determining an absolute superior combination of parameters in predictive models. Because predictive models were built using different populations of patients and different analytical methods, we assumed that our model integrating TZV, PV, PSAD and MR is superior to those developed for other combinations of variables.

Our study has certain limitations. Except for the small sample size, our models were not calibrated using internal and external validation to ensure their utility before being applied to patients. Further studies of clinical practice are therefore required that employ long-term follow-up to evaluate the applicability of our model.

Conclusion {#sec008}
==========

MRI-based PSADTZ and PSAD have potential predictive value for diagnosing PCa and differentiating patients with or without HR-PCa. The application of base models integrated with PZV, TZV and PSADTZ may further improve the predictive accuracy of the diagnosis of PCa and HR-PCa. MRI is used widely in clinical practice. MRI-based model can help clinicians avoid performing unnecessary prostate biopsies and evaluating risk stratification of prostate cancer.

Supporting information {#sec009}
======================

###### Raw data.
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###### 

Click here for additional data file.

We thank Liwen Bianji, Edanz Editing China ([www.liwenbianji.cn/ac](http://www.liwenbianji.cn/ac)), for editing the English text of a draft of this manuscript.

10.1371/journal.pone.0218645.r001

Decision Letter 0

Kim

Isaac Yi

Academic Editor

© 2019 Isaac Yi Kim

2019

Isaac Yi Kim

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

10 Sep 2019

PONE-D-19-16015

The roles of MRI-based prostate volume and associated zone-adjusted prostate-specific antigen concentrations in predicting prostate cancer and high-risk prostate cancer

PLOS ONE

Dear Dr. Li,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Oct 25 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Isaac Yi Kim, MD, PhD

Academic Editor

PLOS ONE

Journal Requirements:

1\. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. In the ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records used in your retrospective study. Specifically, please ensure that you have discussed whether all data were fully anonymized before you accessed them.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Interesting evaluation of MRI to predict prostate cancer.

Major Points:

\- Please elaborate on the 13 core biopsy technique you used. I am more familiar with a 12 core sampling of the peripheral zone. Some urologists also perform anterior biopsies for a total of 14 cores. Targeted biopsies based on multiparametric MRI findings are then done.

\- Were your targeted biopsies \"cognitive\" or did you use MRI-U/S fusion technology such as Artemis or UroNav?

\- What percentage of standard biopsies were positive for cancer vs. those targeting a MRI lesion?

Minor Points:

\- Please format the references according to journal specifications. Numerous citations were missing author names.

Reviewer \#2: Dear Authors:

Please clarify - Ethics Statement on Page 3 is "N/A" and the "Materials and Methods" states "Ethics approval was acquired from the IRB..." Please adjust the Ethics statement accordingly.

Please clarify: "Material and Methods" states this was "retrospective cohort study" and the "Clinical Date and Variable Definition" states ALP and LDH were collected before biopsy. Was that part of the study or was it standard of care. This is important due to the concern above regarding ethics statement.

If you feel appropriate, I would like your thoughts on the existing PIRADs classification used in clinical practice and how it relates to your findings.

Editorial comments:

Consider defining abbreviations in the abstract (PV, PSAD, TZV etc.)

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Biren Saraiya

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0218645.r002

Author response to Decision Letter 0

19 Oct 2019

Thank you for your letter and for the reviewers' comments concerning our manuscript entitled "The roles of MRI-based prostate volume and associated zone-adjusted prostate specific antigen concentrations in predicting prostate cancer and high-risk prostate cancer" (Manuscript number: PONE-D-19-16015). Those comments are all valuable and very helpful for revising and improving our paper, as well as the important guiding significance to our researches. We have studied comments carefully and have made correction which we hope meet with approval. Revised portion are highlighted in a marked-up copy of my manuscript. The main corrections in the paper and the responds to the reviewer's comments are as following:

Responds to the reviewer's comments:

Reviewer \#1:

1\. Please elaborate on the 13 core biopsy technique you used. I am more familiar with a 12 core sampling of the peripheral zone. Some urologists also perform anterior biopsies for a total of 14 cores. Targeted biopsies based on multiparametric MRI findings are then done.

Response: Thank you for suggesting us to make a more clear statement of the 13-core biopsy technique that we used in our clinical work. As we mentioned in our manuscript, four and two cores were acquired from the left PZ and left TZ, respectively, and four and two cores were acquired from the right PZ and right TZ, respectively. The last core was examined for abnormalities found in imageological examination. The number of biopsy cores still remains inconclusive. In our routine clinical work, we perform standard TRUS-guided 13-core prostate biopsy for patient.

2\. Were your targeted biopsies \"cognitive\" or did you use MRI-U/S fusion technology such as Artemis or UroNav?

Response: We are sorry for our negligence of the method of our targeted biopsies. We did use cognitive fusion technology in the last core of biopsy.

3\. What percentage of standard biopsies were positive for cancer vs. those targeting a MRI lesion?

Response: Thank you for putting forward such a valuable question. The last core, so called cognitive biopsy, was a part of systematic biopsies. We didn't compare the positve rate of each core.

4\. Please format the references according to journal specifications. Numerous citations were missing author names.

Response: As Reviewer suggested, our software had something wrong in citing references. But we have fixed it and made correction according to Endnote style file, named "PLoS (Public Library of Science -- all journals)", downloaded from PLOS ONE.

Special thanks to you for your good comments.

Reviewer \#2:

1\. Please clarify - Ethics Statement on Page 3 is "N/A" and the "Materials and Methods" states "Ethics approval was acquired from the IRB..." Please adjust the Ethics statement accordingly.

Response: It is really true as Reviewer suggested that we missed the ethics approval statement. Ethical approval was acquired from the Institutional Review Board of Fujian Medical University Union Hospital. The approval form of consent was obtained by written with approval number of 2018KY078. Now we have submit the ethics approval statement in submission system.

2\. Please clarify: "Material and Methods" states this was "retrospective cohort study" and the "Clinical Date and Variable Definition" states ALP and LDH were collected before biopsy. Was that part of the study or was it standard of care. This is important due to the concern above regarding ethics statement.

Response: Thank you for indicating the potential ethics problem. We routinely perform biochemical analysis on patients, which including ALP and LDH. So it is standard of care for patients.

3\. If you feel appropriate, I would like your thoughts on the existing PIRADs classification used in clinical practice and how it relates to your findings.

Response: Thank you for giving us a hint that will provide a good perspective for improving clinical practice. PIRADs classification is a well-recognized technique that can improve diagnostic performance in prostate cancer. Now we are still working on the PI-RADs v2. And I believe we will get acquainted with it in our next research.

Special thanks to you for your good comments.

Responds to editor comments:

1.We have ensured that our manuscript meets PLOS ONE\'s style requirements through PLOS ONE style templates. If our manuscript still exists any problem, please tell me.

2.The information of patients which we used in our retrospective study has been mentioned in the Clinical data and variable definitions part in our manuscript. We have ensured that all data were fully anonymized before we accessed them.

3.Considering the words limitation of abstract, so we didn't define abbreviations in the abstract. But as editor suggested, now we have defined abbreviations in the abstract, including PCa, PV, PSAD, TZV, PSADTZ, PZV and PSADPZ.

We appreciate for Editors/Reviewers' warm work earnestly, and hope that the correction will meet with approval.

Once again, thank you very much for your comments and suggestions.

###### 

Submitted filename: Response to Reviewers.doc

###### 

Click here for additional data file.

10.1371/journal.pone.0218645.r003

Decision Letter 1

Kim

Isaac Yi

Academic Editor

© 2019 Isaac Yi Kim

2019

Isaac Yi Kim

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

23 Oct 2019

PONE-D-19-16015R1

The roles of MRI-based prostate volume and associated zone-adjusted prostate-specific antigen concentrations in predicting prostate cancer and high-risk prostate cancer

PLOS ONE

Dear Dr. Li,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

1. \"Imageoloical\" is not a standard word used to describe MRI or other imagings. Please revise the relevant sentence appropriately,.

==============================

We would appreciate receiving your revised manuscript by Dec 07 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Isaac Yi Kim, MD, PhD

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0218645.r004

Author response to Decision Letter 1

25 Oct 2019

Dear Editors:

Thank you for your letter concerning our manuscript entitled "The roles of MRI-based prostate volume and associated zone-adjusted prostate specific antigen concentrations in predicting prostate cancer and high-risk prostate cancer" (Manuscript number: PONE-D-19-16015). This comment is all valuable and very helpful for revising and improving our paper, as well as the important guiding significance to our researches. We have studied it carefully and have made correction which we hope meet with approval. Revised portion are highlighted in a marked-up copy of my manuscript. The main correction in the paper and the responds is as following:

1\. 1. \"Imageoloical\" is not a standard word used to describe MRI or other imagings. Please revise the relevant sentence appropriately.

Response: Thank you for indicating our improper use of words. We have corrected this sentence to make it concise and to the point.
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